+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Male Infertility Market Size, Share & Trends Analysis Report by Test (DNA Fragmentation Technique, Oxidative Stress Analysis, Microscopic Examination), by Treatment, by Region, and Segment Forecasts, 2020 - 2027

  • ID: 4312568
  • Report
  • April 2020
  • Region: Global
  • 100 pages
  • Grand View Research
1 of 3

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • Andrology Solutions
  • Aytu BioScience, Inc.
  • Bayer Group
  • Cadila Pharmaceuticals
  • EMD Serono, Inc.
  • Endo International plc
  • MORE
The global male infertility market size is expected to reach USD 5.03 billion by 2027, expanding at a CAGR of 4.7% over the forecast period. Advancements in diagnostic tests and increasing infertility in males are some of the major factors driving the market for male infertility. In addition, lifestyle-associated diseases causing infertility, rising obesity, and a growing aging population are likely to boost the market growth during the forecast period. In the U.S., one-third of infertility cases are due to female factors, one third due to male factors, and the remaining one third is unknown.

DNA fragmentation technique emerged as the largest test segment in the market in 2019 and is expected to maintain its lead during the forecast period. Increasing adoption in developed countries and high cost due to the higher sensitivity and reliable analysis of sperm DNA integrity are the key factors driving the segment.

On the basis of treatment, the Assisted Reproductive Technology (ART) and Varicocele Surgery segment dominated the market for male infertility in 2019 due to its high success rate. Intracytoplasmic sperm injection (ICSI) and in vitro fertilization (IVF) are the most commonly used ARTs. Medications include hormonal therapy and corticosteroids, however, they are effective in very few cases.

Partnerships and agreements among key manufacturers are expected to boost the market growth in the coming years. For instance, in July 2019, Vitrolife entered into a collaboration with Prime Tech for the development and exclusive marketing of the Piezo technique, for improved Intracytoplasmic Sperm Injection (ICSI) procedure in human IVF globally except Malaysia, Thailand, and Japan. Additionally, Vitrolife will initiate the regulatory approval procedures in various markets for the future commercialization of the technology.

Further key findings from the study suggest:
  • Based on the test, DNA fragmentation technique dominated the market in 2019 and is estimated to witness significant growth over the forecast period
  • Oxidative stress analysis test is gaining popularity due to the accurate determination of reactive oxygen species. In March 2018, Aytu BioScience, Inc. received registration from COFEPRIS in Mexico for MiOXSYS System, which is used for diagnosing male infertility
  • Europe dominated the male infertility market in 2019 and is expected to maintain its lead during the forecast period due to the high adoption of costlier treatment, strong diagnosis rate, and increased awareness
  • Asia Pacific is projected to witness substantial growth over the forecast period owing to the increasing investment by several clinics and pharmaceutical companies and a growing healthcare expenditure
  • Some key players of the market are Bayer Healthcare, Inc.; EMD Sereno; Aytu BioScience, Inc.; Halotech DNA SL; Intas Pharmaceuticals Ltd.; Cadila Healthcare Ltd.; Andrology Solutions; and SCSA diagnostics, Inc.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Andrology Solutions
  • Aytu BioScience, Inc.
  • Bayer Group
  • Cadila Pharmaceuticals
  • EMD Serono, Inc.
  • Endo International plc
  • MORE
Chapter 1 Methodology and Scope
1.1 Market Segmentation & Scope
1.1.1 Test
1.1.2 Treatment
1.1.3 Regional Scope
1.1.4 Estimates and Forecast Timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased Database
1.3.2 Author's Internal Database
1.3.3 Secondary Sources
1.3.4 Primary research
1.4 Information or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity flow analysis (Model 1)
1.6.2 Volume price analysis (model 2)
1.7 List of Secondary Sources
1.8 Objectives
1.8.1 Objective - 1
1.8.2 Objective - 2

Chapter 2 Executive Summary
2.1 Market Outlook
2.2 Segment Outlook
2.2.1 Test
2.2.2 Treatment
2.2.3 Region
2.3 Competitive Insights
2.4 Male Infertility Market Outlook, 2019

Chapter 3 Market Variables, Trends & Scope
3.1 Market Lineage Outlook
3.1.1 Parent Market Outlook
3.2 Market Segmentation
3.3 Penetration & Growth Prospect Mapping
3.3.1 Penetration Analysis
3.3.2 Market driver analysis
3.3.2.1 High Adoption of Assisted Reproductive Technology (ART)
3.3.2.2 Increasing incidence of infertility
3.3.2.3 Acquisitions, mergers, and partnerships in the market
3.3.2.4 Technological advancements
3.3.3 Market restraint analysis
3.3.3.1 High cost of treatment
3.4 Male Infertility Market: Business Environment Analysis Tools
3.4.1 Porter’s Five Forces Analysis
3.4.2 PESTEL Analysis
3.5 Clinical Trial Analysis

Chapter 4 Male Infertility Market: Test Analysis
4.1 Male Infertility Test Market Share Analysis, 2019 & 2027
4.2 Male Infertility Test Market: Segment Dashboard:
4.3 Market Size & Forecasts and Trend Analyses, 2015 to 2027 for the Test Segment
4.3.1 DNA Fragmentation Technique
4.3.1.1 DNA fragmentation technique market, 2015 - 2027 (USD Million)
4.3.2 Oxidative Stress Analysis
4.3.2.1 Oxidative stress analysis market, 2015 - 2027 (USD Million)
4.3.3 Microscopic Examination
4.3.3.1 Microscopic Examination market, 2015 - 2027 (USD Million)
4.3.4 Sperm Agglutination
4.3.4.1 Sperm agglutination market, 2015 - 2027 (USD Million)
4.3.5 Computer Assisted Semen Analysis
4.3.5.1 Computer assisted semen analysis market, 2015 - 2027 (USD Million)
4.3.6 Sperm Penetration Assay
4.3.6.1 Sperm penetration assay market, 2015 - 2027 (USD Million)
4.3.7 Others
4.3.7.1 Others market, 2015 - 2027 (USD Million)

Chapter 5 Male Infertility Market: Treatment Analysis
5.1 Male Infertility Treatment Market Share Analysis, 2019 & 2027
5.2 Male Infertility Treatment Market: Segment Dashboard:
5.3 Market Size & Forecasts and Trend Analyses, 2015 to 2027 for the Treatment Segment
5.3.1 ART & Varicocele Surgery
5.3.1.1 ART & varicocele surgery market, 2015 - 2027 (USD Million)
5.3.2 Medication
5.3.2.1 Medication market, 2015 - 2027 (USD Million)

Chapter 6 Male Infertility Market: Regional Analysis
6.1 Male Infertility Regional Market Share Analysis, 2019 & 2027
6.2 Male Infertility Regional Market: Segment Dashboard
6.3 Regional Market Snapshot (Market Size, CAGR, Top Verticals, Key Players, Top Trends)
6.4 SWOT Analysis, by Region
6.4.1 North America
6.4.2 Europe
6.4.3 Asia Pacific
6.4.4 Latin America
6.4.5 MEA
6.5 Market Size, & Forecasts, and Trend Analysis, 2015 to 2027
6.5.1 North America
6.5.1.1 North America male infertility market, 2015 - 2027 (USD Million)
6.5.1.1.1 U.S.
6.5.1.1.1.1 Regulatory & reimbursement scenario
6.5.1.1.1.2 U.S. male infertility market, 2015 - 2027 (USD Million)
6.5.1.1.2 Canada
6.5.1.1.2.1 Regulatory & reimbursement scenario
6.5.1.1.2.2 Canada male infertility market, 2015 - 2027 (USD Million)
6.5.2 Europe
6.5.2.1 Europe male infertility market, 2015 - 2027 (USD Million)
6.5.2.1.1 U.K.
6.5.2.1.1.1 Regulatory & reimbursement scenario
6.5.2.1.1.2 U.K. male infertility market, 2015 - 2027 (USD Million)
6.5.2.1.2 Germany
6.5.2.1.2.1 Regulatory & reimbursement scenario
6.5.2.1.2.2 Germany male infertility market, 2015 - 2027 (USD Million)
6.5.3 Asia Pacific
6.5.3.1 Asia Pacific male infertility market, 2015 - 2027 (USD Million)
6.5.3.1.1 Japan
6.5.3.1.1.1 Regulatory & reimbursement scenario
6.5.3.1.1.2 Japan male infertility market, 2015 - 2027 (USD Million)
6.5.3.1.2 China
6.5.3.1.2.1 Regulatory & reimbursement scenario
6.5.3.1.2.2 China male infertility market, 2015 - 2027 (USD Million)
6.5.4 Latin America
6.5.4.1 Latin America male infertility market, 2015 - 2027 (USD Million)
6.5.4.1.1 Brazil
6.5.4.1.1.1 Regulatory & reimbursement scenario
6.5.4.1.1.2 Brazil male infertility market, 2015 - 2027 (USD Million)
6.5.4.1.2 Mexico
6.5.4.1.2.1 Regulatory & reimbursement scenario
6.5.4.1.2.2 Mexico male infertility market, 2015 - 2027 (USD Million)
6.5.5 Middle East and Africa (MEA)
6.5.5.1 MEA male infertility market, 2015 - 2027 (USD Million)
6.5.5.1.1 South Africa
6.5.5.1.1.1 Regulatory & reimbursement scenario
6.5.5.1.1.2 South Africa male infertility market, 2015 - 2027 (USD Million)

Chapter 7 Competitive Analysis
7.1 Strategic Framework/ Competition Categorization (Key innovators, Market leaders, emerging players
7.2 Vendor Landscape
7.2.1 Strategy Mapping
7.2.2 Launch of New Products
7.2.3 Merger and Acquisition
7.2.4 Product Approvals
7.3 Company Market Position Analysis (Geographic Presence, Product Portfolio, Strategic Initiatives)
7.4 Company Profiles
7.4.1 EMD Serono, Inc.
7.4.1.1 Company overview
7.4.1.2 Financial performance
7.4.1.3 Product benchmarking
7.4.1.4 Strategic initiatives
7.4.2 Endo International plc
7.4.2.1 Company overview
7.4.2.2 Financial performance
7.4.2.3 Product benchmarking
7.4.2.4 Strategic initiatives
7.4.2.5 SWOT analysis
7.4.3 Sanofi
7.4.3.1 Company overview
7.4.3.2 Financial performance
7.4.3.3 Product benchmarking
7.4.3.4 Strategic initiatives
7.4.3.5 SWOT Analysis
7.4.4 Bayer Group
7.4.4.1 Company overview
7.4.4.2 Financial performance
7.4.4.3 Product benchmarking
7.4.4.4 Strategic initiatives
7.4.4.5 SWOT analysis
7.4.5 SCSA Diagnostics
7.4.5.1 Company overview
7.4.5.2 Product benchmarking
7.4.6 Andrology Solutions
7.4.6.1 Company overview
7.4.6.2 Product benchmarking
7.4.7 Halotech DNA SL
7.4.7.1 Company overview
7.4.7.2 Product benchmarking
7.4.7.3 Strategic initiatives
7.4.8 Intas Pharmaceuticals Ltd.
7.4.8.1 Company overview
7.4.8.2 Financial performance
7.4.8.3 Product benchmarking
7.4.8.4 Strategic initiatives
7.4.8.5 SWOT analysis
7.4.9 Aytu BioScience, Inc.
7.4.9.1 Company overview
7.4.9.2 Financial performance
7.4.9.3 Product Benchmarking
7.4.9.4 Strategic initiatives
7.4.9.5 SWOT Analysis
7.4.10 Cadila Pharmaceuticals
7.4.10.1 Company overview
7.4.10.2 Product benchmarking
7.4.10.3 Strategic initiatives
7.4.11 Vitrolife
7.4.11.1 Company overview
7.4.11.2 Financial performance
7.4.11.3 Product benchmarking
7.4.11.4 Strategic initiatives
7.4.11.5 SWOT Analysis

Chapter 8 Recommendations
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • EMD Serono, Inc.
  • Endo International plc
  • Sanofi
  • Bayer Group
  • SCSA Diagnostics
  • Andrology Solutions
  • Halotech DNA SL
  • Intas Pharmaceuticals Ltd.
  • Aytu BioScience, Inc.
  • Cadila Pharmaceuticals
  • Vitrolife
Note: Product cover images may vary from those shown
Adroll
adroll